Caring for the world one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Business & Industry
- Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
- Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
- Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
- Bayer transforms pharma business through breakthrough innovation in healthcare
- Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
Research & Development
- Obesity, impaired metabolic health and COVID-19
- COVID-19 has multiple faces
- Metformin use reduces risk of death for patients with COVID-19 and diabetes
- New England Journal of Medicine publishes COVID-19 treatment trial results
- Scientists identify 'immune cop' that detects SARS-CoV-2
- New findings help explain how COVID-19 overpowers the immune system
- New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2